Article
FDA creates new oncology office and program
The FDA has consolidated three existing areas within the Center for Drug Evaluation and Research to form the Office of Oncology Drug Products.
Related Videos
Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
Fred Saad, MD, FRCP, reacts to FDA approval of darolutamide in mCSPC
The Role of Bone-Targeted Therapies
Topline Results From Recent NMIBC Trials
Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs
First-Line mHSPC Therapy: AR Inhibitors vs Chemotherapy
Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
Using Ultrasensitive PSA Assays in Routine Practice
Related Content
